Newsletter Tool

PM Tracker

Today’s Big News

Oct 4, 2024

J&J drops phase 2 dengue candidate as part of ongoing move away from vaccines

BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda

Relay cuts more staff in efforts to save $50M a year

FDA approves Exact Sciences’ next-gen Cologuard Plus home screening test

GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply

US' top IV fluid maker Baxter voices uncertainty about recovery timeline at NC facility hit by Helene

Flexible mRNA vaccine protects mice from deadly C. diff infections, including recurring cases

Featured

J&J drops phase 2 dengue candidate as part of ongoing move away from vaccines

By James Waldron

Johnson & Johnson’s deprioritization of its infectious disease pipeline has claimed another victim in the form of its dengue virus vaccine mosnodenvir.

BeiGene launches PD-1 drug Tevimbra at 10% discount to Merck's Keytruda

By Angus Liu

BeiGene is pricing Tevimbra at a 10% discount to other PD-1 therapies available in second-line esophageal squamous cell carcinoma.

Relay cuts more staff in efforts to save $50M a year

By Gabrielle Masson

Precision medicines biotech Relay Therapeutics is shedding about 10% of its workforce in efforts to streamline the organization.

FDA approves Exact Sciences’ next-gen Cologuard Plus home screening test

By Conor Hale

Cologuard Plus represents the next generation of the company's mainstay, at-home screening test for colorectal cancer.

GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply

By Angus Liu

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines.

US' top IV fluid maker Baxter voices uncertainty about recovery timeline at NC facility hit by Helene

By Fraiser Kansteiner

While progress is already being made after Hurricane Helene, which resulted in water “permeating” Baxter’s large IV fluid production plant in North Carolina, the company cautioned that it does not yet have a timeline for when operations will be back online.

Flexible mRNA vaccine protects mice from deadly C. diff infections, including recurring cases

By Darren Incorvaia

The bacterium Clostridioides difficile is named “difficult” for a reason. Originally it was hard to grow in the lab, and now it’s the source of gut infections that are tough to treat. About half a million people in the U.S. contract C. diff every year, often from hospitals, and even once treated it’s common for the microbe to reinfect patients again and again.

Ultragenyx tweaks gene therapy dosing to dial up efficacy after seeing signs of activity

By Nick Paul Taylor

A minority of patients taking Ultragenyx Pharmaceutical’s Wilson disease gene therapy UX701 have come off standard-of-care drugs, leading the biotech to enroll a new cohort on a tweaked regimen designed to dial up the efficacy.

American Society for Meningitis Prevention paints the town purple and blue for World Meningitis Day

By Andrea Park

A nonprofit dedicated to improving vaccination rates to eradicate meningococcal meningitis is brightening things up this World Meningitis Day.

Chutes & Ladders—Prothena promotes one exec while another leaves

By Darren Incorvaia,Zoey Becker

Prothena, a company focused on neurodegenerative diseases, is shaking up its C-suite. The exec moves were announced just a day after the science underlying Prothena’s Parkinson’s drug prasinezumab was implicated in a massive research misconduct scandal but are unrelated, a company spokesperson told Fierce in an email.

Fierce podcasts

Don’t miss an episode

Breaking down BIOSECURE—Industry implications, what comes next

This week on "The Top Line," Fierce Pharma’s Fraiser Kansteiner and Arnold & Porter’s Dan Kracov break down the BIOSECURE Act's potential impact on the life sciences industry and what comes next after the House of Representatives' recent vote.

ESMO, WCLC lung cancer data spark hope—and debate

Former VA Secretary Shulkin on the future of health policy

Resources

Whitepaper

Accelerating Timelines to Clinic with GPEx® Lightning

Unlock the Future of Biotherapeutics with Catalent Biologics!

Epilepsy Clinical Trials

Finding an effective epilepsy treatment can be arduous. Download this brochure to delve into how IQVIA's expertise and innovative strategic approach can streamline the clinical trial process, helping to get new therapies to patients who need them sooner.